Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gillian Barratt

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Molecules (Basel, Switzerland)|April 12, 2022
The Potential of 2-Substituted Quinolines as Antileishmanial Drug CandidatesPhilippe M Loiseau, Kaluvu Balaraman, Gillian Barratt, et al.
Toxicology and Applied Pharmacology|September 4, 2017
A cell impedance-based real-time in vitro assay to assess the toxicity of amphotericin B formulationsJean Menotti, Alexandre Alanio, Aude Sturny-Leclère, et al.
International Journal of Pharmaceutics|July 21, 2012
Aerosolized liposomal amphotericin B: prediction of lung deposition, in vitro uptake and cytotoxicityMélanie Fauvel, Cécile Farrugia, Nicolas Tsapis, et al.
Antimicrobial Agents and Chemotherapy|March 30, 2004
Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium berghei-infected miceVanessa C F Mosqueira, Philippe M Loiseau, Christian Bories, et al.
International Journal of Pharmaceutics|July 12, 2022
Pharmacokinetics, biodistribution, and activity of Amphotericin B-loaded nanocochleates on the Leishmania donovani murine visceral leishmaniasis modelAntonio Lipa Castro, Sébastien Pomel, Catherine Cailleau, et al.
International Journal of Pharmaceutics|May 9, 2021
Cochleate formulations of Amphotericin b designed for oral administration using a naturally occurring phospholipidAntonio Lipa-Castro, Valérie Nicolas, Angelina Angelova, et al.
Expert Opinion on Drug Delivery|June 26, 2012
Trends in rheumatic fever: clinical aspects and perspectives in prophylactic treatmentsKattya Gyselle De Holanda E Silva, Gillian Barratt, Anselmo Gomes De Oliveira, et al.
International Journal of Pharmaceutics|November 18, 2021
Repurposing chlorpromazine for anti-leukaemic therapy by nanoparticle encapsulationEdvin Tang Gundersen, Jan-Lukas Førde, Benedicte Sjo Tislevoll, et al.
Life Sciences|February 17, 2007
Cardiotoxicity reduction induced by halofantrine entrapped in nanocapsule devicesElaine Amaral Leite, Andrea Grabe-Guimarães, Homero Nogueira Guimarães, et al.
Antimicrobial Agents and Chemotherapy|November 26, 2003
Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin BMalika Larabi, Vanessa Yardley, Philippe M Loiseau, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Molecules (Basel, Switzerland)|April 12, 2022
The Potential of 2-Substituted Quinolines as Antileishmanial Drug CandidatesPhilippe M Loiseau, Kaluvu Balaraman, Gillian Barratt, et al.
Toxicology and Applied Pharmacology|September 4, 2017
A cell impedance-based real-time in vitro assay to assess the toxicity of amphotericin B formulationsJean Menotti, Alexandre Alanio, Aude Sturny-Leclère, et al.
International Journal of Pharmaceutics|July 21, 2012
Aerosolized liposomal amphotericin B: prediction of lung deposition, in vitro uptake and cytotoxicityMélanie Fauvel, Cécile Farrugia, Nicolas Tsapis, et al.
Antimicrobial Agents and Chemotherapy|March 30, 2004
Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium berghei-infected miceVanessa C F Mosqueira, Philippe M Loiseau, Christian Bories, et al.
International Journal of Pharmaceutics|July 12, 2022
Pharmacokinetics, biodistribution, and activity of Amphotericin B-loaded nanocochleates on the Leishmania donovani murine visceral leishmaniasis modelAntonio Lipa Castro, Sébastien Pomel, Catherine Cailleau, et al.
International Journal of Pharmaceutics|May 9, 2021
Cochleate formulations of Amphotericin b designed for oral administration using a naturally occurring phospholipidAntonio Lipa-Castro, Valérie Nicolas, Angelina Angelova, et al.
Expert Opinion on Drug Delivery|June 26, 2012
Trends in rheumatic fever: clinical aspects and perspectives in prophylactic treatmentsKattya Gyselle De Holanda E Silva, Gillian Barratt, Anselmo Gomes De Oliveira, et al.
International Journal of Pharmaceutics|November 18, 2021
Repurposing chlorpromazine for anti-leukaemic therapy by nanoparticle encapsulationEdvin Tang Gundersen, Jan-Lukas Førde, Benedicte Sjo Tislevoll, et al.
Life Sciences|February 17, 2007
Cardiotoxicity reduction induced by halofantrine entrapped in nanocapsule devicesElaine Amaral Leite, Andrea Grabe-Guimarães, Homero Nogueira Guimarães, et al.
Antimicrobial Agents and Chemotherapy|November 26, 2003
Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin BMalika Larabi, Vanessa Yardley, Philippe M Loiseau, et al.
Pageof 6